Clinical Trials Directory

Trials / Completed

CompletedNCT03071081

Study for Safety and Tolerability of TOP1288 Administered Orally in Healthy Subjects

A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TOP1288 Oral Single Ascending and Multiple Doses in Healthy Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
37 (actual)
Sponsor
Topivert Pharma Ltd · Industry
Sex
Male
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

This study evaluates the safety and tolerability of TOP1288 oral single ascending and multiple doses in healthy subjects.

Conditions

Interventions

TypeNameDescription
DRUGTOP1288Oral TOP1288
DRUGPlacebo to TOP1288Oral placebo to TOP1288

Timeline

Start date
2017-02-08
Primary completion
2017-06-02
Completion
2017-06-02
First posted
2017-03-06
Last updated
2018-09-20

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT03071081. Inclusion in this directory is not an endorsement.